Relapse incidence

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%

Pediatric-style chemotherapy was associated with higher 5-year cumulative relapse incidence compared to allogeneic HCT, though the timing of relapse differed: relapse was initially more likely with HC

Effect: decline; 5-year relapse 34% vs 23%